Moderna (NASDAQ:MRNA) Stock Jumps 4.6% - Here's Why

Key Points

• Moderna shares rose 4.6% to about $207.97, with trading volume roughly 38% above average.
• Moderna and Merck’s personalized melanoma vaccine achieved its Phase 3 endpoint, reducing recurrence or death by 42% when combined with Keytruda versus Keytruda alone.
• Despite the clinical success, valuation concerns remain: William Blair downgraded the stock, analysts’ consensus rating is “Hold,” and the average price target of $107.10 is well below the current share price.

Shares of Moderna, Inc. (NASDAQ:MRNA - Get Free Report) shot up 4.6% during mid-day trading on Tuesday. The stock traded as high as $208.87 and last traded at $207.97. Approximately 17,511,972 shares changed hands during mid-day trading, an increase of 38% from the average session volume of 12,691,296 shares. The stock had previously closed at $198.85.

Moderna News Summary

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna and Merck’s personalized melanoma vaccine, intismeran, achieved its Phase 3 primary endpoint. Combined with Keytruda, it reduced the risk of recurrence or death by 42% and distant metastasis or death by 38% versus Keytruda alone. The data were presented at ESMO 2026 and accepted for publication in The New England Journal of Medicine, providing important clinical validation. Moderna Phase 3 melanoma vaccine validation
• Positive Sentiment: An analyst price target for Moderna’s depositary receipt was increased 14.39% to ARS11,759.61, signaling continued long-term optimism from at least one market observer. Moderna depositary receipt price target increase
• Neutral Sentiment: CEO Stéphane Bancel says Moderna’s mRNA platform and personalized manufacturing capabilities provide a competitive advantage. Investors are watching whether the company can scale patient-specific vaccine production and convert the clinical success into commercial revenue. Moderna CEO discusses cancer vaccine strategy
• Negative Sentiment: William Blair downgraded Moderna from Outperform to Market Perform, citing valuation after a roughly 545% year-to-date rally. The firm’s call adds to concerns that much of the future cancer-vaccine opportunity is already reflected in the stock. William Blair downgrades Moderna on valuation
• Negative Sentiment: Although the trial succeeded, the 42% recurrence-risk reduction was below investor hopes based on earlier Phase 2 results of approximately 49%. The result, combined with Moderna’s continuing losses and shrinking COVID revenue, has caused investors to reassess a valuation largely dependent on an unapproved product with no sales. Merck and Moderna cancer vaccine trial analysis

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Bradesco Corretora raised Moderna to an "outperform" rating in a research report on Friday, August 28th. Weiss Ratings restated a "sell (d-)" rating on shares of Moderna in a research note on Wednesday, September 9th. Wolfe Research upgraded shares of Moderna from an "underperform" rating to a "peer perform" rating in a research note on Tuesday, August 25th. CLSA raised shares of Moderna to an "outperform" rating in a report on Friday, August 28th. Finally, Citigroup reissued a "sell" rating on shares of Moderna in a report on Friday. Six investment analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $107.10.

Moderna Price Performance

The company has a current ratio of 2.29, a quick ratio of 2.18 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $83.03 billion, a PE ratio of -26.03 and a beta of 1.09. The firm has a 50 day moving average price of $173.86 and a 200 day moving average price of $82.87.

Moderna (NASDAQ:MRNA - Get Free Report) last released its earnings results on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, beating the consensus estimate of ($2.03) by $0.06. The company had revenue of $145.00 million for the quarter, compared to the consensus estimate of $102.93 million. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%. Moderna's quarterly revenue was up 2.1% compared to the same quarter last year. During the same period in the previous year, the business earned ($2.13) earnings per share. Research analysts anticipate that Moderna, Inc. will post -6.11 earnings per share for the current year.

Insider Buying and Selling at Moderna

In related news, CFO Jamey Mock sold 34,836 shares of Moderna stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $134.49, for a total transaction of $4,685,093.64. Following the sale, the chief financial officer owned 59,375 shares of the company's stock, valued at approximately $7,985,343.75. This trade represents a 36.98% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Klinger sold 3,471 shares of the stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total transaction of $485,766.45. Following the sale, the insider directly owned 74,129 shares of the company's stock, valued at approximately $10,374,353.55. This trade represents a 4.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 197,251 shares of company stock valued at $33,875,904 over the last ninety days. 10.80% of the stock is currently owned by company insiders.

Institutional Trading of Moderna

A number of large investors have recently added to or reduced their stakes in MRNA. Great Lakes Retirement Inc. bought a new stake in shares of Moderna in the 3rd quarter valued at approximately $2,560,000. Jacobsen Capital Management purchased a new position in Moderna during the third quarter worth $257,000. Asset Management One Co. Ltd. increased its position in Moderna by 3.4% during the third quarter. Asset Management One Co. Ltd. now owns 21,713 shares of the company's stock valued at $4,181,000 after acquiring an additional 711 shares during the last quarter. MADDEN SECURITIES Corp bought a new position in Moderna during the third quarter valued at $55,000. Finally, DMC Group LLC bought a new stake in shares of Moderna in the 3rd quarter worth about $563,000. Institutional investors own 75.33% of the company's stock.

About Moderna

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company's research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.

Moderna's commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.